PurposeDiagnosing primary mitochondrial diseases (MDs) is challenging in clinical practice. The mitochondrial disease criteria (MDC) have been developed to quantify the clinical picture and evaluate the probability of an underlying MD and the need for a muscle biopsy. In this new genetic era with next-generation sequencing in routine practice, we aim to validate the diagnostic value of MDC.MethodsWe retrospectively studied MDC in a multicenter cohort of genetically confirmed primary MD patients.ResultsWe studied 136 patients (61 male, 91 nuclear DNA (nDNA) mutations). Forty-five patients (33%) had probable MD and 69 (51%) had definite MD according to the MDC. A muscle biopsy was performed in 63 patients (47%). Patients with nDNA mutations versus mitochondrial DNA mutations were younger (6.4 ± 9.7 versus 19.5 ± 17.3 y) and had higher MDC (7.07 ± 1.12/8 versus 5.69 ± 1.94/8). At a cutoff of 6.5/8, the sensitivity to diagnose patients with nDNA mutations is 72.5% with a positive predictive value of 69.5%. In the nDNA mutation group, whole-exome sequencing could diagnose patients with lower scores (MDC (6.84 ± 1.51/8) compared to Sanger sequencing MDC (7.44 ± 1.13/8, P = 0.025)). Moreover 7/8 patients diagnosed with possible MD by MDC were diagnosed by whole-exome sequencing.ConclusionMDC remain very useful in the clinical diagnosis of MD, in interpreting whole-exome results and deciding on the need for performing muscle biopsy.

Department of Paediatrics and Metabolic Center University Hospitals Leuven Department of Development and Regeneration KU Leuven Leuven Belgium

Department of Pediatrics 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Institute of Genetic Medicine Newcastle University Newcastle upon Tyne UK

Medical Genetics Centre Munich Germany

Monique and Jacques Roboh Department of Genetic Research Hadassah Hebrew University Medical Centre Jerusalem Israel

The Department of Genetic and Metabolic Diseases Hadassah Hebrew University Medical Centre Jerusalem Israel

Tulane University Medical School Hayward Genetics Center New Orleans Louisiana USA

See more in PubMed

Hum Mutat. 2013 Dec;34(12):1721-6 PubMed

Brain. 2016 Mar;139(Pt 3):782-94 PubMed

Sci Transl Med. 2012 Jan 25;4(118):118ra10 PubMed

Nucleic Acids Res. 2016 Jan 4;44(D1):D1251-7 PubMed

EMBO Mol Med. 2016 Mar 31;8(4):311-27 PubMed

Science. 2015 Sep 25;349(6255):1494-9 PubMed

J Transl Med. 2016 Jun 12;14 (1):174 PubMed

EMBO Mol Med. 2015 Nov 26;7(12 ):1503-12 PubMed

Genet Med. 2014 Dec;16(12):962-71 PubMed

Neurology. 2006 Nov 28;67(10):1823-6 PubMed

Neurology. 2002 Nov 12;59(9):1402-5 PubMed

JIMD Rep. 2017;33:61-68 PubMed

Int J Biochem Cell Biol. 2014 Mar;48:60-5 PubMed

J Inherit Metab Dis. 2015 May;38(3):437-43 PubMed

Nat Rev Neurol. 2013 Aug;9(8):429-44 PubMed

Neurology. 2002 Nov 12;59(9):1406-11 PubMed

J Inherit Metab Dis. 2015 May;38(3):387-8 PubMed

JAMA. 2014 Jul 2;312(1):68-77 PubMed

Brain. 2011 Nov;134(Pt 11):3333-41 PubMed

Biochim Biophys Acta. 2004 Dec 6;1659(2-3):115-20 PubMed

J Med Genet. 2012 Apr;49(4):234-41 PubMed

Neurology. 2013 Apr 23;80(17):1577-83 PubMed

PLoS Genet. 2016 Jan 07;12(1):e1005679 PubMed

AANA J. 2013 Jun;81(3):237-43 PubMed

Biochim Biophys Acta. 2016 Aug;1857(8):1326-1335 PubMed

Genet Med. 2015 Sep;17(9):689-701 PubMed

J Inherit Metab Dis. 2015 Jul;38(4):641-53 PubMed

J Inherit Metab Dis. 2012 Sep;35(5):749-59 PubMed

J Inherit Metab Dis. 2012 Sep;35(5):737-47 PubMed